Site 105 — Beijing, Beijing Municipality

Public research footprint of Site 105, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Immunoglobulin A Nephropathy · Pemphigus Vulgaris · Pemphigus Foliaceus · Heart Failure With Reduced Ejection Fraction

Recently updated registry entries

NCT07096843 — A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy (Recruiting)
NCT06822790 — Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (Recruiting)
NCT05248646 — Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Site 105?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.